期刊文献+

他汀类药物作用机制的研究进展 被引量:22

Progresses of statins mechanisms
在线阅读 下载PDF
导出
摘要 他汀类药物为3-羟基-3-甲基戊二酰辅酶A(HMG-COA)还原酶抑制剂,是临床高胆固醇血症和高低密度脂蛋白胆固醇血症的首选药物,广泛应用于冠心病的一、二级预防.近年来研究发现,他汀类药物对心血管疾病的防治不仅仅依赖于其降脂作用,他汀类药物还可抑制血管炎症反应,修复和改善血管内皮功能,减轻血管重塑,稳定斑块等,进而抑制动脉粥样硬化的形成;此外,他汀类药物还干扰一系列脂质中间体的合成代谢及蛋白质的异戊烯化.本文对他汀类药物降脂以外的其他重要生物学作用进行综述. 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors,referred to as "statins",are the major prescribed medication for hypercholesterolemia and high low density lipoprotein cholesterol,therefore are widely used in primary and secondary prevention of coronary heart disease.Recent studies have found that statins not only possess lipid-lowering effect,but also inhibit vascular inflammation,repair and improve endothelial function,reduce vascular remodeling,promote plaque stabilization in preventing cardiovascular disease;in addition,statins also interfere with a series of lipid intermediates metabolism and protein prenylation.This article reviewed the other activities of statins besides lipid-lowering effect.
出处 《中国医药》 2016年第3期442-447,共6页 China Medicine
基金 国家自然科学基金(81270285) 国家临床重点专科建设项目(2013-2014) 北京市医院管理局重点医学专业发展计划(ZYLX201303) 北京市医院管理局“登峰”计划专项经费资助项目(DFL20150601) 首都卫生发展科研专项项目(首发2011-2006-04) 北京市保健科研课题项目(京13-11、京13-12)
关键词 他汀类药物 非降脂作用 多效性 机制 Statins Independent lipid-lowering Pleiotropic Mechanism
作者简介 通信作者:周玉杰,Email:azzyj12@163.com
  • 相关文献

参考文献64

  • 1WHO. Global status report on non-communicable diseases [ R ]. Geneva: 2011.
  • 2WHO. Global atlas on cardiovascular disease prevention and control[ R]. Geneva: 2011.
  • 3Mathers CD, Dejan L. Projections of global mortality and burden of disease from 2002 to 2030 [ J ]. PLoS Medicine, 2006,3 ( 11 ) : M42442. DOI: 10. 1371/journal. pmed. 0030442.
  • 4王文,朱曼璐,王拥军,等.《中国心血管病报告2012》概要[J].中国循环杂志,2013,28(6):408-412.
  • 5Zhou Q, Liao JK. Pleiotropic effects of statins : basic research and clinical perspectives[ J]. Circ J, 2010,74 ( 5 ) : 818-826. DOI: 10. 1253/circj. CJ-10-0110.
  • 6Wang CY, Liu PY, Liao JK, et al. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results [ J ]. Trends Mol Med, 2008,14( 1 ) :37-44. DOI: 10. 1016/j. molmed. 2007. 11. 004.
  • 7Bonow RO, Mann DL, Zipes DP, et al. Braunwald's heart disease[M]. 9th edi6on. Philadelphia: Saunders Elsevier ,2012:987. Giannotti G, Landmesser U. Endothelial dysfunction as an early sign of atherosclerosis [ J ]. Herz, 2007,32 ( 7 ) : 568-572. DOI : 10. 1007/s00059-007-3073-1.
  • 8Wojnicz R, Wilczek K, Nowalany-Kozielska E, et al. Usefulness of atorvastatin in patients with heart failure due to inflammatory dilated cardiomyopathy and elevated cholesterol levels [ J ]. 2006, 97 (6) :899-904. DOt: http ://dx. doi. org/10. 1016/j. amjcard. 2005.09. 142.
  • 9Wassmann S, Laufs U, Biiumer AT, et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species [ J ]. Hypertension, 2001,37 ( 6 ) : 1450-1457. DOI: 10. 1161/01. HYP. 37.6. 1450.
  • 10Liu PY, Liu YW, Lin LJ, et al. Evidence for statin pleiotropy in humans : differential effects of statins and ezetimibe on rho-associ- ated coiled-coil containing protein kinase activity, endothelial function, and inflammation[ J]. Circulation, 2009,119 ( 1 ) : 131- 138. DOI: 10. 1074/jbc. M311550200.

二级参考文献62

共引文献120

同被引文献150

引证文献22

二级引证文献103

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部